119 related articles for article (PubMed ID: 35339231)
1. Artificial Intelligence-Powered Hematoxylin and Eosin Analyzer Reveals Distinct Immunologic and Mutational Profiles among Immune Phenotypes in Non-Small-Cell Lung Cancer.
Park J; Cho HG; Park J; Lee G; Kim HS; Paeng K; Song S; Park G; Ock CY; Chae YK
Am J Pathol; 2022 Apr; 192(4):701-711. PubMed ID: 35339231
[TBL] [Abstract][Full Text] [Related]
2. Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer.
Park S; Ock CY; Kim H; Pereira S; Park S; Ma M; Choi S; Kim S; Shin S; Aum BJ; Paeng K; Yoo D; Cha H; Park S; Suh KJ; Jung HA; Kim SH; Kim YJ; Sun JM; Chung JH; Ahn JS; Ahn MJ; Lee JS; Park K; Song SY; Bang YJ; Choi YL; Mok TS; Lee SH
J Clin Oncol; 2022 Jun; 40(17):1916-1928. PubMed ID: 35271299
[TBL] [Abstract][Full Text] [Related]
3. Using Artificial Intelligence to Identify Tumor Microenvironment Heterogeneity in Non-Small Cell Lung Cancers.
DuCote TJ; Naughton KJ; Skaggs EM; Bocklage TJ; Allison DB; Brainson CF
Lab Invest; 2023 Aug; 103(8):100176. PubMed ID: 37182840
[TBL] [Abstract][Full Text] [Related]
4. Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer.
Lozano MD; Labiano T; Echeveste J; Gurpide A; Martín-Algarra S; Zhang G; Sharma A; Palma JF
Cancer Cytopathol; 2015 Apr; 123(4):230-6. PubMed ID: 25529460
[TBL] [Abstract][Full Text] [Related]
5. Deep learning-based tumor microenvironment segmentation is predictive of tumor mutations and patient survival in non-small-cell lung cancer.
Rączkowska A; Paśnik I; Kukiełka M; Nicoś M; Budzinska MA; Kucharczyk T; Szumiło J; Krawczyk P; Crosetto N; Szczurek E
BMC Cancer; 2022 Sep; 22(1):1001. PubMed ID: 36131239
[TBL] [Abstract][Full Text] [Related]
6. Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma.
Thunnissen E; Boers E; Heideman DA; Grünberg K; Kuik DJ; Noorduin A; van Oosterhout M; Pronk D; Seldenrijk C; Sietsma H; Smit EF; van Suylen R; von der Thusen J; Vrugt B; Wiersma A; Witte BI; den Bakker M
Virchows Arch; 2012 Dec; 461(6):629-38. PubMed ID: 23064619
[TBL] [Abstract][Full Text] [Related]
7. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
8. T-cell exhaustion interrelates with immune cytolytic activity to shape the inflamed tumor microenvironment.
Cai MC; Zhao X; Cao M; Ma P; Chen M; Wu J; Jia C; He C; Fu Y; Tan L; Xue X; Yu Z; Zhuang G
J Pathol; 2020 Jun; 251(2):147-159. PubMed ID: 32222046
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component.
Pan Y; Wang R; Ye T; Li C; Hu H; Yu Y; Zhang Y; Wang L; Luo X; Li H; Li Y; Shen L; Sun Y; Chen H
Chest; 2014 Mar; 145(3):473-479. PubMed ID: 24158231
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of machine learning approaches to classify tumor mutation burden in lung adenocarcinoma using histopathology images.
Sadhwani A; Chang HW; Behrooz A; Brown T; Auvigne-Flament I; Patel H; Findlater R; Velez V; Tan F; Tekiela K; Wulczyn E; Yi ES; Mermel CH; Hanks D; Chen PC; Kulig K; Batenchuk C; Steiner DF; Cimermancic P
Sci Rep; 2021 Aug; 11(1):16605. PubMed ID: 34400666
[TBL] [Abstract][Full Text] [Related]
11. Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape.
Xia W; Mao W; Chen R; Lu R; Liu F; He Y; Wang S; Li X; Zheng M
Med Sci Monit; 2019 Nov; 25():8764-8776. PubMed ID: 31746315
[TBL] [Abstract][Full Text] [Related]
12. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
13. Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients.
Song P; Yang D; Wang H; Cui X; Si X; Zhang X; Zhang L
Thorac Cancer; 2020 Jun; 11(6):1647-1654. PubMed ID: 32342665
[TBL] [Abstract][Full Text] [Related]
14. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
15. Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets.
Grilley-Olson JE; Hayes DN; Moore DT; Leslie KO; Wilkerson MD; Qaqish BF; Hayward MC; Cabanski CR; Yin X; Socinski MA; Stinchcombe TE; Thorne LB; Allen TC; Banks PM; Beasley MB; Borczuk AC; Cagle PT; Christensen R; Colby TV; Deblois GG; Elmberger G; Graziano P; Hart CF; Jones KD; Maia DM; Miller CR; Nance KV; Travis WD; Funkhouser WK
Arch Pathol Lab Med; 2013 Jan; 137(1):32-40. PubMed ID: 22583114
[TBL] [Abstract][Full Text] [Related]
16. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
Martín Martorell P; Huerta M; Compañ Quilis A; Abellán R; Seda E; Blesa S; Chaves FJ; Dualde Beltrán D; Roselló Keränen S; Franco J; Insa A
Clin Lung Cancer; 2017 Nov; 18(6):e395-e402. PubMed ID: 28550959
[TBL] [Abstract][Full Text] [Related]
17. Artificial Intelligence-Powered Prediction of
Terada Y; Takahashi T; Hayakawa T; Ono A; Kawata T; Isaka M; Muramatsu K; Tone K; Kodama H; Imai T; Notsu A; Mori K; Ohde Y; Nakajima T; Sugino T; Takahashi T
JCO Clin Cancer Inform; 2022 Sep; 6():e2200070. PubMed ID: 36162012
[TBL] [Abstract][Full Text] [Related]
18. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
19. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
[TBL] [Abstract][Full Text] [Related]
20. Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors.
Jang HJ; Lee HS; Ramos D; Park IK; Kang CH; Burt BM; Kim YT
J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1598-1610.e3. PubMed ID: 31879171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
